Therapeutic efficacy of engineered exosomes in Alzheimer's disease: A systematic review and meta-analysis of preclinical animal models
Clinical Snapshot
PICO Framework
| P — Population | Preclinical animal models of Alzheimer's disease |
| I — Intervention | Engineered exosomes (modified extracellular vesicles) |
| C — Comparator | Disease models and natural exosomes |
| O — Outcomes | Spatial learning and memory (Morris water maze), amyloid beta pathology, tau phosphorylation, neuroinflammatory markers |
Bottom Line
This systematic review and meta-analysis examines engineered exosomes as a potential therapeutic approach for Alzheimer's disease in preclinical animal models. While the review follows PRISMA guidelines and addresses comprehensive outcomes including cognitive function and pathological markers, the evidence quality is acknowledged as low to very low. The findings suggest potential benefits in spatial learning and memory tasks and reduction of amyloid beta burden compared to natural exosomes, but evidence for tau phosphorylation effects remains limited. The authors appropriately emphasize that conclusions should be interpreted cautiously and that rigorous preclinical studies and clinical trials with standardized protocols are needed before clinical translation. For Australian clinicians, this represents early-stage research that may inform future therapeutic development but has no immediate clinical application. The technology would require substantial regulatory evaluation by the TGA before any clinical consideration.
Key Findings
P Value: Not reported
Effect Size: Not specified in abstract
Primary Outcome: Improved Morris water maze performance with engineered exosomes
Nnt Or Sensitivity: Reduced amyloid beta burden and pro-inflammatory cytokines compared to natural exosomes
Confidence Interval: Not reported
Clinical Application
Low - requires significant technological development and regulatory approval Would require TGA approval as novel therapeutic; currently no PBS listing pathway for engineered exosomes; research opportunities through NHMRC funding Currently limited to research settings; not ready for clinical application
Abstract
Engineered exosomes are modified extracellular vesicles designed to enhance targeting and cargo delivery, and they have been proposed as a therapeutic strategy for Alzheimer's disease. We systematically reviewed preclinical animal studies evaluating engineered exosomes, synthesized evidence from comparisons with disease models and with natural exosomes, and reported the study in accordance with the PRISMA 2020 checklist. Outcomes included spatial learning and memory assessed by the Morris water maze, amyloid beta pathology, tau phosphorylation, and neuroinflammatory markers. Random effects meta-analyses suggested that engineered exosomes improved Morris water maze performance and reduced amyloid beta burden and pro-inflammatory cytokines compared with natural exosomes, whereas evidence regarding tau phosphorylation was limited and largely qualitative, and the overall certainty of evidence was low to very low. These findings support further investigation of engineered exosomes, but conclusions should be interpreted cautiously until confirmed by rigorously designed and blinded preclinical studies and clinical trials with standardized protocols.
References
- 1.Li, A., Peng, W., Wu, B., Li, C., & Yang, J. (2026). Therapeutic efficacy of engineered exosomes in Alzheimer's disease: A systematic review and meta-analysis of preclinical animal models. Neuroscience. https://doi.org/10.1016/j.neuroscience.2026.03.019
Related Research
Sleep medicine reviews
Machine and deep learning in REM sleep behavior disorder: a scoping review and analysis of reporting quality
3 Aug 2026
Neurological research
Federated deep learning model for epilepsy seizure detection using electroencephalogram (EEG) signal
2 Aug 2026
Journal of psychiatric research
Systematic review of machine learning and deep learning models for EEG-based detection of depression.
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service